Loop IV AAV Capsid Engineering for Retinal Cell Binding

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current AAV capsids used in gene therapy for ocular diseases lack efficiency and specificity in cell surface binding, internalization, trafficking, and uncoating, necessitating the development of novel modified capsids to improve gene delivery.

Innovation Solution

A modified AAV capsid polypeptide with a peptide inserted into loop IV, comprising a specific amino acid sequence, enhances gene delivery efficiency by improving cell surface binding and internalization.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If current AAV capsids are used for gene therapy, then the basic gene delivery function is achieved, but the efficiency and specificity in cell surface binding, internalization, trafficking, and uncoating are insufficient

Engineering Contradiction:
Improvegene delivery efficiencyVSAvoidcell surface binding specificity
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent applies local quality by inserting a peptide sequence specifically into loop IV of the AAV capsid structure. This localized modification targets the specific region responsible for cell surface interaction, thereby improving binding specificity and internalization efficiency without altering the entire capsid structure. The peptide insertion at this specific location enhances the interaction with retinal cell surface receptors while maintaining overall capsid integrity.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent employs parameter changes by modifying the amino acid sequence of the capsid protein through peptide insertion. This changes the physical and chemical properties of the capsid surface, specifically enhancing its affinity for retinal cell surface receptors. The modification alters binding kinetics, internalization rates, and trafficking efficiency, thereby improving overall gene delivery performance.

Inventive Principle:
Principle #35Parameter changes

2Productivity

If modified AAV capsids are developed to improve gene delivery efficiency, then transduction efficiency for retinal cells is enhanced, but the complexity of capsid engineering increases

Engineering Contradiction:
Improvetransduction efficiencyVSAvoidcapsid engineering complexity
Core Design Contradiction:
ProductivityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the capsid modification into distinct functional components: the parental AAV capsid structure and the inserted peptide sequence. This modular approach allows for systematic optimization of each component independently. The peptide insertion is designed as a separate element that can be independently characterized and optimized for retinal cell targeting, simplifying the overall engineering process.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent employs universality by designing a peptide sequence with multiple functions: it enhances cell surface binding, facilitates internalization, and improves trafficking efficiency. This multi-functional peptide insertion addresses multiple limitations of the parental capsid simultaneously, thereby achieving comprehensive improvement in gene delivery performance through a single modification strategy.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentUS12485188B2Recombinant adeno-associated virus with modified AAV capsid polypeptides
Publication Date: 2025.12.02 SKYLINE THERAPEUTICS LTD
  • US12485188B2 patent drawing
  • US12485188B2 patent drawing
  • US12485188B2 patent drawing

AI summary

The present invention relates to a modified adeno-associated virus (AAV) capsid polypeptide and a novel recombinant adeno-associated virus (rAAV) comprising the modified AAV capsid polypeptide for delivering the gene product for the therapy. The present invention also relates to a pharmaceutical composition comprising the rAAV of the present invention, and a method of treating a retinal disease comprising the administration of the rAAV or the pharmaceutical composition of the present invention to an eye of a subject in need thereof.